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What is TB? 
Tuberculosis (TB) is a disease caused by bacteria that are spread from person to person through the air. TB usually attacks the 
lungs, but it can also attack and damage any part of the body, such as the brain, kidneys, or spine. A person with TB can die 
without treatment. 
What are the symptoms of TB?
The general symptoms of TB disease include feelings of sickness or weakness, weight loss, fever, and night sweats. The 
symptoms of TB disease of the lungs also include coughing, chest pain, and coughing up blood. Symptoms of TB disease in 
other parts of the body depend on the area affected.
How is TB spread?
TB bacteria are put into the air when a person with TB disease of the lungs or throat coughs, sneezes, or speaks. These germs 
can stay in the air for several hours, depending on the environment. Persons who breathe in the air containing these TB germs 
can become infected; this is called latent TB infection. People with TB disease are most likely to spread the germs to people 
they spend time with every day, such as family members or coworkers, since it usually takes prolonged exposure to someone 
with TB disease for someone to become infected.
Latent TB Infection vs. TB Disease 
What is latent TB infection?
Persons with latent TB infection do not feel sick, do not have any symptoms, and cannot spread TB bacteria to others. They 
have TB bacteria in their bodies, but do not have TB disease, which is both symptomatic and infectious (see below). The only 
sign of latent TB infection is a positive reaction to the tuberculin skin test or TB blood tests. However, not everyone infected 
with TB bacteria becomes sick. Without treatment, about 5 to 10 percent of infected persons will develop TB disease at some 
time in their lives. 
What is TB disease?
In some people, TB bacteria overcome the defenses of the immune system and begin to multiply, resulting in the progression 
from latent TB infection to TB disease. Without treatment, the bacteria continue to multiply and destroy the body’s tissue. 
Some people develop TB disease soon after infection (within the first two years), while others develop TB disease later if their 
immune system becomes weak, such as those who are also infected with HIV. Persons with TB disease may spread TB bacteria 
to others. Persons suspected of having TB disease should be referred for a medical evaluation and additional tests. If not 
treated properly, TB disease can be fatal.
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TB in the United States
How many cases of TB occur in the United States?
Latent TB Infection: Based on the most recent nationally representative data available,  
CDC estimates more than 11.2 million people in the United States, or about 4 percent of  
the total population, have latent TB infection.1 
TB Disease: The most recent data show that a total of 9,951 cases  
of TB disease were reported in the United States in 2012  
(3.2 cases per 100,000 population)*— an all-time low.  
Foreign-born individuals (Figure 1) and racial/ethnic  





Figure 1. Proportion of TB 
Cases by National Origin, 2012
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Figure 2. TB Rates by Race/Ethnicity, 2012
Drug-Resistant Tuberculosis 
What is multidrug-resistant tuberculosis (MDR TB)? 
Multidrug-resistant TB is TB that is resistant to at least two of the best anti-TB drugs, isoniazid and rifampin. These drugs are 
considered first-line drugs and are recommended for treatment of all persons with drug-susceptible TB disease. MDR TB 
accounted for 1.6 percent (127 total cases) of all TB cases in the United States with drug-susceptibility testing completed in 
2011, the most recent year for which complete drug-susceptibility results are available.  
What is extensively drug-resistant tuberculosis (XDR TB)? 
Extensively drug-resistant TB is a relatively rare type of MDR TB. XDR TB is defined as TB which is resistant to isoniazid and 
rifampin, as well as resistant to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, 
kanamycin, or capreomycin). Because XDR TB is resistant to first- and second-line drugs, patients are left with treatment 
options that are much less effective. One case of XDR TB was reported in the United States in 2012. 
How does drug resistance happen? 
Resistance to anti-TB drugs can occur when these drugs are misused or mismanaged. Examples include when patients do not 
complete their full course of treatment; when health-care providers prescribe the wrong treatment, dose, or length of time 
for taking the drugs; when the supply of drugs is not always available; or when the drugs are of poor quality. Individuals with 
drug-resistant TB disease can also transmit the resistant strain of the disease directly to others. 
* 2012 numbers are based on preliminary data
1 Bennett DE et al. Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55. 
2 CDC. Trends in Tuberculosis  — United States, 2012. MMWR 22 March 2013.
MARCH 2013 3
TB Treatment 
How is latent TB infection treated? 
Treating latent TB infection is essential to controlling and eliminating TB in the United States, because it substantially reduces 
the risk that the infection will progress to TB disease. Certain individuals with latent TB infection, such as those with weakened 
immune systems (due to HIV, a recent organ transplant, or other reasons) and persons recently infected with TB bacteria,  
are at increased risk of developing TB disease, and every effort should be made to ensure those persons begin — and 
complete — the entire course of treatment for latent TB infection. 
For decades, the standard treatment regimen for latent TB infection has consisted of six to nine months of daily isoniazid. 
Although this regimen is very effective, ensuring that those who need treatment both begin and complete the lengthy 
isoniazid regimen is challenging. However, a new regimen that can significantly shorten and simplify the course of treatment 
for latent TB infection has proven as effective as daily isoniazid in a large multinational trial. In December 2011, CDC issued 
guidelines on the use of this new treatment option, which cuts the doses required for treatment from 270 daily doses (nine 
months) of isoniazid alone to just 12 once-weekly doses of rifapentine and isoniazid together. The 12-dose regimen adds to 
other current latent TB infection treatment options and does not replace those treatment options. CDC is working to increase 
awareness of this new regimen among health care providers for use in treating patients with latent TB infection. 
How is TB disease treated? 
Treatment of TB disease requires multiple medications that must be taken for six to nine months (or longer for drug-resistant 
TB) depending on the regimen selected. (For information on specific treatment regimens, see CDC’s TB Treatment Guidelines: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.) 
It is critical to ensure that individuals with TB disease successfully complete the prescribed treatment regimen in order 
to prevent the development of drug resistant disease. To maximize the likelihood of completion of therapy, treatment 
management plans emphasize “directly observed therapy,” in which a health care professional observes the patient taking 
the prescribed medications. CDC also recommends that each patient’s management plan be individualized to include 
measures that may facilitate adherence to the drug regimen, such as social service support, housing assistance, and referral 
for treatment of substance abuse. 
Immunization 
Is a TB vaccine available? 
BCG (bacille Calmette-Guerin) is a vaccine for TB disease; however, the vaccine does not always protect people from getting 
TB. Because BCG is used in many countries with a high prevalence of TB, many foreign-born persons living in the United States 
have been BCG-vaccinated. However, BCG is not generally recommended for use in the United States because of the low risk 
of TB infection, variable effectiveness of the vaccine against TB in the lungs, and known interference between the vaccine and 
the TB skin test. 
If you are a member of the news media and need more information, please visit www.cdc.gov/nchhstp/Newsroom  
or contact the News Media Line at CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
(404-639-8895 or NCHHSTPMediaTeam@cdc.gov).
